Dr Shubhra Sinha

2024

Journal - Research Article

Fan, C., Eedara, B. B., Sinha, S., Udden, M. K. M., Doyle, C., Banu, S., & Das, S. C. (2024). Triple combination dry powder formulation of pretomanid, moxifloxacin, and pyrazinamide for treatment of multidrug-resistant tuberculosis. International Journal of Pharmaceutics, 654, 123874. doi: 10.1016/j.ijpharm.2024.123984

2023

Journal - Research Article

Eedara, B. B., Fan, C., Sinha, S., Khadka, P., & Das, S. C. (2023). Inhalable combination powder formulations for treating latent and multidrug-resistant tuberculosis: Formulation and in vitro characterization. Pharmaceutics, 15, 2354. doi: 10.3390/pharmaceutics15092354

Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2023). Inhalable dry powder containing remdesivir and disulfiram: Preparation and in vitro characterization. International Journal of Pharmaceutics, 645, 123411. doi: 10.1016/j.ijpharm.2023.123411

Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2023). Spray-dried inhalable microparticles combining remdesivir and ebselen against SARS-CoV-2 infection. Pharmaceutics, 15, 2229. doi: 10.3390/pharmaceutics15092229

Montgomerie, I., Bird, T. W., Palmer, O. R., Mason, N. C., Pankhurst, T. E., Lawley, B., … Harfoot, R., … Sinha, S., … on behalf of the VAANZ Group. (2023). Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants. iScience. Advance online publication. doi: 10.1016/j.isci.2023.106256

Conference Contribution - Published proceedings: Full paper

Das, S. C., Khadka, P., Sinha, S., Katare, R., Hill, P. C., & Dummer, J. (2023). Towards the clinical translation of inhaled rifampicin for tuberculosis. In R. N. Dalby, J. Peart, D. Traini, P. M. Young & J. D. Suman (Eds.), Respiratory drug delivery. 2023, (pp. 11-18). Richmond, VA: RDD Online. [Full Paper]

Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2023). Development of inhalable dry powders combining replication and protease inhibitors of SARS-CoV-2. Proceedings of the 34th Drug Delivery to the Lungs (DDL) Conference. 34, (pp. 389-392). Retrieved from https://ddl-conference.com

2022

Journal - Research Article

Adhikari, B. R., Sinha, S., Lyons, N., Pletzer, D., Lamont, I., Gordon, K. C., & Das, S. C. (2022). Inhalable ceftazidime-roflumilast powder targeting infection and inflammation: Influence of incorporating roflumilast into ceftazidime-leucine co-amorphous formulation. European Journal of Pharmaceutics & Biopharmaceutics, 180, 260-268. doi: 10.1016/j.ejpb.2022.10.005

Saha, T., Sinha, S., Harfoot, R., Quiñones Mateu, M. E., & Das, S. C. (2022). Manipulation of spray-drying conditions to develop an inhalable ivermectin dry powder. Pharmaceutics, 14(7), 1432. doi: 10.3390/pharmaceutics14071432

Adhikari, B. R., Sinha, S., Gordon, K. C., & Das, S. C. (2022). Amino acids improve aerosolization and chemical stability of potential inhalable amorphous spray-dried ceftazidime for Pseudomonas aeruginosa lung infection. International Journal of Pharmaceutics, 621, 121799. doi: 10.1016/j.ijpharm.2022.121799

Conference Contribution - Published proceedings: Abstract

Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2022). Development of remdesivir and ebselen containing inhalable dry powder for COVID-19. Proceedings of the Australasian Pharmaceutical Science Association (APSA) and the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Joint Conference. 566. Retrieved from https://www.asceptasm.com

Conference Contribution - Poster Presentation (not in published proceedings)

Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2022, November). Inhalable dry powder of synergistic drug combinations to treat COVID-19. Poster session presented at the Otago Global Health Institute (OGHI) 14th Annual Conference: Reimagining Partnerships, Dunedin, New Zealand.

Conference Contribution - Verbal presentation and other Conference outputs

Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2022, November). Inhalable dry powder containing remdesivir and disulfiram for COVID-19. Verbal presentation at the School of Pharmacy Research Day, Dunedin, New Zealand.

Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2022, November). Remdesivir and ebselen containing inhalable dry powder against SARS-CoV-2. Verbal presentation at the New Zealand Controlled Release Society (NZCRS) Symposium, Auckland, New Zealand.

Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2022, November). Inhalable antivirals for SARS-CoV-2 infections. Verbal presentation at the Bioengineering@Otago Showcase, [Online].

2021

Journal - Research Article

Momin, M. A. M., Adhikari, B. R., Sinha, S., Larson, I., & Das, S. C. (2021). Roflumilast powders for chronic obstructive pulmonary disease: Formulation design and the influence of device, inhalation flow rate, and storage relative humidity on aerosolization. Pharmaceutics, 13, 1254. doi: 10.3390/pharmaceutics13081254

Khadka, P., Sinha, S., Tucker, I. G., Dummer, J., Hill, P. C., Katare, R., & Das, S. C. (2021). Pharmacokinetics of rifampicin after repeated intra-tracheal administration of amorphous and crystalline powder formulations to Sprague Dawley rats. European Journal of Pharmaceutics & Biopharmaceutics, 162, 1-11. doi: 10.1016/j.ejpb.2021.02.011

Khadka, P., Sinha, S., Tucker, I. G., Dummer, J., Hill, P. C., Katare, R., & Das, S. C. (2021). Studies on the safety and the tissue distribution of inhaled high-dose amorphous and crystalline rifampicin in a rat model. International Journal of Pharmaceutics, 597, 120345. doi: 10.1016/j.ijpharm.2021.120345

Conference Contribution - Published proceedings: Full paper

Khadka, P., Sinha, S., Tucker, I. G., Dummer, J., Hill, P. C., Katare, R., & Das, S. C. (2021). High-dose inhaled rifampicin powder formulations: Preparation, in vitro characterization and in vivo evaluation. Proceedings of the Drug Delivery to the Lungs (DDL) Conference (Vol. 32). Retrieved from https://ddl-conference.com

Conference Contribution - Published proceedings: Abstract

Khadka, P., Sinha, S., Hill, P. C., Dummer, J., Tucker, I. G., Katare, R. G., & Das, S. C. (2021). In vitro and in vivo evaluation of high-dose inhaled rifampicin powder formulations for tuberculosis treatment. New Zealand Medical Journal, 134(1547), (pp. 139). Retrieved from https://www.nzma.org.nz/journal

2020

Conference Contribution - Published proceedings: Abstract

Khadka, P., Sinha, S., Tucker, I. G., Dummer, J., Hill, P. C., Katare, R., & Das, S. C. (2020). Safety of a single high-dose inhaled rifampicin in Sprague Dawley rats. Journal of Aerosol Medicine & Pulmonary Drug Delivery, 33(2), (pp. A11). doi: 10.1089/jamp.2020.ab01.abstracts

2019

Journal - Research Article

Momin, M. A. M., Rangnekar, B., Sinha, S., Cheung, C.-Y., Cook, G. M., & Das, S. C. (2019). Inhalable dry powder of Bedaquiline for pulmonary tuberculosis: In vitro physiochemical characterization, antimicrobial activity and safety studies. Pharmaceutics, 11(10), 502. doi: 10.3390/pharmaceutics11100502

Rangnekar, B., Momin, M. A. M., Eedara, B. B., Sinha, S., & Das, S. C. (2019). Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis. International Journal of Pharmaceutics, 570, 118689. doi: 10.1016/j.ijpharm.2019.118689

Momin, M. A. M., Rangnekar, B., Larson, I., Sinha, S., & Das, S. C. (2019). Dry powder formulation combining bedaquiline with pyrazinamide for latent and drug-resistant tuberculosis. Advanced Powder Technology, 30(11), 2473-2482. doi: 10.1016/j.apt.2019.07.016

Momin, M. A. M., Sinha, S., Tucker, I. G., & Das, S. C. (2019). Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis. Drug Development & Industrial Pharmacy, 45(8), 1321-1331. doi: 10.1080/03639045.2019.1609494

Conference Contribution - Published proceedings: Abstract

Khadka, P., Sinha, S., Katare, R., & Das, S. C. (2019). Identification of suitable polymorphic forms of rifampicin for inhaled high dose delivery. Proceedings of the Australasian Pharmaceutical Science Association (APSA) Annual Conference: Working Together Toward Better Health Outcomes. (pp. 20). Retrieved from http://www.apsa-online.org

Momin, M. A. M., Sinha, S., Tucker, I. G., & Das, S. C. (2019). High dose spray-dried powders for treating tuberculosis. Journal of Aerosol Medicine & Pulmonary Drug Delivery, 32(2), (pp. A23). doi: 10.1089/jamp.2019.ab01.abstracts

2018

Journal - Research Article

Eedara, B. B., Rangnekar, B., Sinha, S., Doyle, C., & Cavallaro, A. (2018). Development and characterization of high payload combination dry powders of anti-tubercular drugs for treating pulmonary tuberculosis. European Journal of Pharmaceutical Sciences, 118, 216-226. doi: 10.1016/j.ejps.2018.04.003

Momin, M. A. M., Tucker, I. G., Doyle, C. S., Denman, J. A., Sinha, S., & Das, S. C. (2018). Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections. International Journal of Pharmaceutics, 541(1-2), 26-36. doi: 10.1016/j.ijpharm.2018.02.026

2017

Journal - Research Article

Sinha, S., Kuo, C.-Y., Ho, J. K., White, P. J., Jazayeri, J. A., & Pouton, C. W. (2017). A suicidal strain of Listeria monocytogenes is effective as a DNA vaccine delivery system for oral administration. Vaccine, 35(40), 5115-5122. doi: 10.1016/j.vaccine.2017.08.014

Momin, M. A. M., Sinha, S., Tucker, I. G., Doyle, C., & Das, S. C. (2017). Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis. International Journal of Pharmaceutics, 528(1-2), 107-117. doi: 10.1016/j.ijpharm.2017.06.004

Conference Contribution - Published proceedings: Full paper

Das, S. C., Fan, C., Eedara, B. B., & Sinha, S. (2017). A triple combination anti-tubercular dry powder formulation for treating both drug susceptible and multidrug resistant tuberculosis: Formulation and in vitro characterization. Proceedings of the Drug Delivery to the Lungs (DDL) Conference: Shaping the Next 25 Years of Nasal and Pulmonary Drug Delivery. (pp. 206-209). Retrieved from https://ddl-conference.com